Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
The effect of spike mutations on SARS-CoV-2 neutralization
Cell Reports, Volume 34, No. 12, Article 108890, Year 2021
Notification
URL copied to clipboard!
Description
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy. © 2021 The Authors; This study describes neutralization by antibodies and convalescent sera of SARS-CoV-2 spike mutants. Rees-Spear et al. show that SARS-CoV amino acid substitutions and the B.1.1.7 variant can block monoclonal antibody neutralization and that serum samples collected following mild illness are less resilient to spike variation than those following severe illness. © 2021 The Authors
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC7936541/bin/mmc1.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC7936541/bin/mmc2.pdf
Authors & Co-Authors
Muir, Luke
United Kingdom, London
University College London
Griffith, Sarah A.
United Kingdom, London
University College London
Heaney, Judith
United Kingdom, London
University College London Hospitals Nhs Foundation Trust
Graham, Carl
United Kingdom, London
King's College London
Seow, Jeffrey
United Kingdom, London
King's College London
Roustan, Chloé
United Kingdom, London
The Francis Crick Institute
Houlihan, Catherine F.
United Kingdom, London
University College London Hospitals Nhs Foundation Trust
United Kingdom, London
University College London
Sanders, Rogier W.
Netherlands, Amsterdam
Amsterdam Institute for Infection and Immunity
Gupta, Ravindra K.
United Kingdom, Cambridge
University of Cambridge
Cherepanov, Peter P.
United Kingdom, London
The Francis Crick Institute
Stauss, Hans J.
United Kingdom, London
University College London
Nastouli, Eleni
United Kingdom, London
University College London Hospitals Nhs Foundation Trust
United Kingdom, London
The Francis Crick Institute
United Kingdom, London
University College London
Doores, Katie J.
United Kingdom, London
King's College London
McCoy, Laura E.
United Kingdom, London
University College London
Statistics
Citations: 176
Authors: 14
Affiliations: 6
Identifiers
Doi:
10.1016/j.celrep.2021.108890
ISSN:
22111247
Research Areas
Covid